{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-052083","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.826418+00:00","generated_at":"2026-05-16T20:34:42.521920+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Senti Bio Q3 net loss $18.1M; cash $12.2M; ASH data ahead","bullets":["Cash and cash equivalents $12.2M as of Sep 30, 2025, down from $48.3M at Dec 31, 2024.","Net loss $18.1M ($0.69 per share) for Q3 2025; R&D expense $10.5M, G&A $6.4M.","Phase 1 SENTI-202 in AML: updated clinical data to be presented at ASH meeting Dec 6-9, 2025.","Abstracts accepted for oral and poster presentations at ASH; company will host webcast.","No revenue; pre-commercial biotech focused on gene circuit platform for cell therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-052083","json":"https://secwatch.observer/filing/0001628280-25-052083.json","markdown":"https://secwatch.observer/filing/0001628280-25-052083.md","text":"https://secwatch.observer/filing/0001628280-25-052083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000162828025052083/0001628280-25-052083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000162828025052083/snti-20251113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:34:42.521920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}